Polyseq Biotech Co.,Ltd. ("the Company") was founded in 2021 as a leading enterprise in the field of domestic nanopore gene sequencing technology innovation. With a core technological foundation built on its independently developed nanopore sequencing chemical system and novel membrane protein nanopore atomic-level structures, the Company focuses on achieving core performance goals of "system stability, long read length, high throughput, low cost, high accuracy, and portability." It is dedicated to the independent R&D, manufacturing, and commercialization of nanopore gene sequencers and their supporting chips and reagents.

The Company was initiated by multiple internationally renowned professors and possesses a world-class R&D and management team. The founder, Researcher Huang Yihua, is a recipient of the National Science Fund for Distinguished Young Scholars, a leading talent in technological innovation under the National Ten Thousand Talent Program, and the chief scientist of the "Third-Generation Sequencer" project under the National Key R&D Program of the Ministry of Science and Technology. The R&D team he leads covers diverse fields such as molecular biology, microfluidics, genomics, and bioinformatics. Leveraging interdisciplinary strengths, the team possesses comprehensive capabilities for end-to-end technological R&D. It has undertaken multiple national-level research projects, including the "Transformative Technologies" Special Project of the Ministry of Science and Technology and major instrument development projects of the Chinese Academy of Sciences, establishing itself as an emerging force in the R&D and innovation of next-generation nanopore sequencing technology.

The Company is committed to achieving technological breakthroughs at the industry's source, broadening the application boundaries of nanopore sequencing technology through continuous independent innovation, and propelling China's gene sequencing technology into a new stage of independent and controllable development. By collaborating with upstream and downstream partners in the life sciences and biotechnology sectors, it aims to jointly build an open, synergistic, and win-win industrial ecosystem. The Company strives to bring advanced gene detection technologies to institutions at all levels, providing domestically developed technological solutions for fields such as life sciences, rapid pathogen detection, disease control, and judicial forensics, thereby breaking the long-standing reliance on imports and safeguarding China's biological information security.

Since its establishment, the Company has completed several rounds of financing, receiving strategic support from leading institutions and companies such as DG Capital, Tsinghua Ventures, Wondfo Biotech, and Guoke Venture Capital. Moving forward, the Company will continue to drive industrial upgrading through technological innovation, support the implementation of the "Healthy China" strategy, and inject core momentum into the high-quality development of China's biotechnology industry.